Avadel Pharmaceuticals PLC expected to post a loss of 6 cents a share - Earnings Preview

Avadel Pharmaceuticals

08/11/2024 16:32

* Avadel Pharmaceuticals PLC  AVDL.OQ   AVDL.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 12 for the period ending September 30 2024
    * The Dublin-based  company is expected to report a
593.0% increase in revenue to $48.607 million from $7.01 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Avadel Pharmaceuticals
PLC is
for a loss of 6 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avadel
Pharmaceuticals PLC is $24.00​, above​ its last closing price
of $15.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.17       -0.16      -0.14     Beat    10
 Mar. 31 0001  -0.20       -0.21      -0.30     Missed  -44.4
 Dec. 31 2023  -0.23       -0.26      -0.29     Missed  -11.8​
 Jan. 1 0001   -0.38       -0.37      -0.41     Missed  -10.1
 ​​Jun.        -0.38       -0.38      -0.83     Missed  -116
 30 2023                                                
 Jan. 1 0001   -0.34       -0.38      -0.48     Missed  -27.4​
 Dec. 31 2022  -0.30       -0.27      -0.46     Missed  -69.7
 Sep. 30 2022  -0.21       -0.25      -0.33     Missed  -30.3
 This summary was machine generated November 8 at 16:31 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)